Latest BK Trustee Addendum filing (432 pages)...Ex
Post# of 36563
(Total Views: 519)
Posted On: 10/20/2022 1:13:31 PM
Latest BK Trustee Addendum filing (432 pages)...Exhibit list below
If you want to read this you'll have to download the file, I'm not posting 432 pages into the box...
Here is the link to the whole filing (expires in 7 days)
https://we.tl/t-2Lt1R781rB
APPENDIX
Marc Barmat, Chapter 7 Trustee of Generex Biotechnology Corp. hereby files this
Appendix of documents in support of Trustee's Motion For Entry Of An Order (I) Approving
Stalking Horse Bid And Stalking Horse EPA, (II) Approving Bid Procedures And Bid Protections
In Connection With The Sale Of Debtor's Equity In Two Subsidiaries, (III) Approving The Form
And Manner Of Notice Of Sale, (IV) Scheduling An Auction And Sale Hearing And (V)
Approving The Sale Of The Equity Free And Clear Of Liens, Claims And Encumbrances (ECF
No. 56) filed on October 14, 2022 in this bankruptcy proceeding.
INDEX TO APPENDIX
EXHIBIT 1 Form 10-K for Generex Biotechnology, Corp. for the fiscal year ended
July 31, 2020
EXHIBIT 2 Form 8-K for Generex Biotechnology, Corp. dated November 27, 2018
EXHIBIT 3 Binding Letter of Intent dated November 26, 2018
EXHIBIT 4 Stock Purchase Agreement
EXHIBIT 5 Form 8-K for Generex Biotechnology Corp. dated January 7, 2018 [sic]
EXHIBIT 6 Amendment Agreement
Case 22-13166-PDR Doc 63 Filed 10/19/22 Page 1 of 3
66858798;1 - 2 -
EXHIBIT 7 Stock Purchase Agreement dated January 14, 2019; Promissory Note
dated January 14, 2019; and Pledge and Security Agreement dated January
14, 2019
EXHIBIT 8 Share Exchange Agreement Between Olaregen Therapeutix LLC and
Generex Biotechnology Corp. dated August 16, 2019
EXHIBIT 9 Letter Agreement from Olaregen Therapeutix Inc. to Generex
Biotechnology Corporation dated February 14, 2020
EXHIBIT 10 Form 10-Q for Generex Biotechnology, Corp. for the quarterly period
ended April 30, 2021
EXHIBIT 11 Form 8-K for Generex Biotechnology, Corp. filed August 15, 2003 for the
period ending August 8, 2003
EXHIBIT 12 State of Delaware Certificate of Amendment of Certificate of
Incorporation
EXHIBIT 13 Form 10-K for NuGenerex Immuno-Oncology, Inc.
EXHIBIT 14 Form 10-Q for NuGenerex Immuno-Oncology, Inc. for the quarterly
period ended April 30, 2021
EXHIBIT 15 Order Instituting Administrative Proceedings and Notice of Hearing
Pursuant to Section 12(j) of the Securities Exchange Act of 1934
EXHIBIT 16 Order Appointing Receiver Over Judgment Debtor’s Property
If you want to read this you'll have to download the file, I'm not posting 432 pages into the box...
Here is the link to the whole filing (expires in 7 days)
https://we.tl/t-2Lt1R781rB
APPENDIX
Marc Barmat, Chapter 7 Trustee of Generex Biotechnology Corp. hereby files this
Appendix of documents in support of Trustee's Motion For Entry Of An Order (I) Approving
Stalking Horse Bid And Stalking Horse EPA, (II) Approving Bid Procedures And Bid Protections
In Connection With The Sale Of Debtor's Equity In Two Subsidiaries, (III) Approving The Form
And Manner Of Notice Of Sale, (IV) Scheduling An Auction And Sale Hearing And (V)
Approving The Sale Of The Equity Free And Clear Of Liens, Claims And Encumbrances (ECF
No. 56) filed on October 14, 2022 in this bankruptcy proceeding.
INDEX TO APPENDIX
EXHIBIT 1 Form 10-K for Generex Biotechnology, Corp. for the fiscal year ended
July 31, 2020
EXHIBIT 2 Form 8-K for Generex Biotechnology, Corp. dated November 27, 2018
EXHIBIT 3 Binding Letter of Intent dated November 26, 2018
EXHIBIT 4 Stock Purchase Agreement
EXHIBIT 5 Form 8-K for Generex Biotechnology Corp. dated January 7, 2018 [sic]
EXHIBIT 6 Amendment Agreement
Case 22-13166-PDR Doc 63 Filed 10/19/22 Page 1 of 3
66858798;1 - 2 -
EXHIBIT 7 Stock Purchase Agreement dated January 14, 2019; Promissory Note
dated January 14, 2019; and Pledge and Security Agreement dated January
14, 2019
EXHIBIT 8 Share Exchange Agreement Between Olaregen Therapeutix LLC and
Generex Biotechnology Corp. dated August 16, 2019
EXHIBIT 9 Letter Agreement from Olaregen Therapeutix Inc. to Generex
Biotechnology Corporation dated February 14, 2020
EXHIBIT 10 Form 10-Q for Generex Biotechnology, Corp. for the quarterly period
ended April 30, 2021
EXHIBIT 11 Form 8-K for Generex Biotechnology, Corp. filed August 15, 2003 for the
period ending August 8, 2003
EXHIBIT 12 State of Delaware Certificate of Amendment of Certificate of
Incorporation
EXHIBIT 13 Form 10-K for NuGenerex Immuno-Oncology, Inc.
EXHIBIT 14 Form 10-Q for NuGenerex Immuno-Oncology, Inc. for the quarterly
period ended April 30, 2021
EXHIBIT 15 Order Instituting Administrative Proceedings and Notice of Hearing
Pursuant to Section 12(j) of the Securities Exchange Act of 1934
EXHIBIT 16 Order Appointing Receiver Over Judgment Debtor’s Property
(3)
(0)